David S. Hong

1994–2026 年に発表

別表記
David S Hong
305
論文数
40,972
被引用数
110
h 指数
293
i10 指数

被引用数

David S. Hong の年別被引用数1956 年: 被引用 1 件1995 年: 被引用 2 件1997 年: 被引用 2 件1998 年: 被引用 1 件2000 年: 被引用 3 件2001 年: 被引用 1 件2002 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 4 件2005 年: 被引用 6 件2006 年: 被引用 12 件2007 年: 被引用 13 件2008 年: 被引用 21 件2009 年: 被引用 45 件2010 年: 被引用 73 件2011 年: 被引用 88 件2012 年: 被引用 158 件2013 年: 被引用 209 件2014 年: 被引用 225 件2015 年: 被引用 280 件2016 年: 被引用 300 件2017 年: 被引用 396 件2018 年: 被引用 427 件2019 年: 被引用 1,502 件2020 年: 被引用 2,122 件2021 年: 被引用 2,577 件2022 年: 被引用 2,234 件2023 年: 被引用 1,858 件2024 年: 被引用 2,886 件2025 年: 被引用 1,713 件2026 年: 被引用 75 件1957〜1994 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 6,049 件、この内訳の 27.7%中国: 引用元論文 2,850 件、この内訳の 13.1%イタリア: 引用元論文 1,304 件、この内訳の 6%イギリス: 引用元論文 1,095 件、この内訳の 5%ドイツ: 引用元論文 1,013 件、この内訳の 4.6%フランス: 引用元論文 863 件、この内訳の 4%スペイン: 引用元論文 708 件、この内訳の 3.2%日本: 引用元論文 705 件、この内訳の 3.2%カナダ: 引用元論文 658 件、この内訳の 3%オーストラリア: 引用元論文 521 件、この内訳の 2.4%オランダ: 引用元論文 521 件、この内訳の 2.4%スイス: 引用元論文 464 件、この内訳の 2.1%
0%27.7%その他 23.3%

分野

  • Medicine54.8%
  • Biochemistry, Genetics and Molecular Biology35.5%
  • Immunology and Microbiology4%
  • Engineering1%
  • Neuroscience0.9%
  • Computer Science0.8%
  • その他3%

トピック

  • Cancer Genomics and Diagnostics4.4%
  • Cancer Immunotherapy and Biomarkers4.4%
  • Lung Cancer Treatments and Mutations3.8%
  • MicroRNA in disease regulation1.9%
  • Colorectal Cancer Treatments and Studies1.9%
  • Immunotherapy and Immune Responses1.8%
  • その他81.8%

共著者

全論文

検索で開く
  1. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Haby Henary, Tara Arvedson, Victor J. Cee, J. Russell Lipford - Nature 2019 被引用: 2,303

  2. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li - New England Journal of Medicine 2020 被引用: 1,687

  3. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman - New England Journal of Medicine 2018 被引用: 2,728

  4. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

    著者: , , , , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2020 被引用: 912

  5. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 994

  6. Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 468

  7. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolina Salguero, Koji Sasaki, Anand Kumar Singh, Vivek Subbiah, Apostolia M. Tsimberidou, Quanyun A. Xu, Musa Yılmaz, Qi Zhang, Yuan Li, Christopher A. Bristow, Meenakshi B. Bhattacharjee, Stefano Tiziani, Timothy P. Heffernan, Christopher P. Vellano, Philip Jones, Cobi J. Heijnen, Annemieke Kavelaars, Joseph R. Marszalek, Marina Konopleva - Nature Medicine 2023 被引用: 377

  8. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

    著者: , , , , , , , , , - Investigational New Drugs 2016 被引用: 884

  9. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jing Wang, Blerina Resuli, Lorenza Landi, Shu-Chi Tseng, Mizuki Nishino, Subba R. Digumarthy, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Ara A. Vaporciyan, George R. Blumenschein, Jianjun Zhang, Dwight H. Owen, Collin M. Blakely, Giannis Mountzios, Catherine A. Shu, Christine M. Bestvina, Marina Chiara Garassino, Kristen A. Marrone, Jhanelle E. Gray, Sandip Pravin Patel, Amy L. Cummings, Heather A. Wakelee, Juergen Wolf, Giorgio V. Scagliotti, Federico Cappuzzo, Fabrice Barlési, Pradnya D. Patil, Leylah Drusbosky, Don L. Gibbons, Funda Meric‐Bernstam, J. Jack Lee, John V. Heymach, David S. Hong, Rebecca S. Heist, Mark M. Awad, Ferdinandos Skoulidis - Cancer Discovery 2023 被引用: 181

  10. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 288

  11. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ben Z. Stanger, Simona Cristea, Scott W. Lowe, Timour Baslan, Eliezer M. Van Allen, Joseph D. Mancias, Emily Chan, Abraham Anderson, Yuliya V. Katlinskaya, Alex K. Shalek, David S. Hong, Shubham Pant, Jill Hallin, Kenna Anderes, Peter Olson, Timothy P. Heffernan, Seema Chugh, James G. Christensen, Anirban Maitra, Brian M. Wolpin, Srivatsan Raghavan, Jonathan A. Nowak, Peter Winter, Stephanie K. Dougan, Andrew J. Aguirre - Cancer Discovery 2024 被引用: 234

  12. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dzmitry G. Batrakou, Erin Van Winkle, Erica Elefant, Armin Ghobadi, Amanda F. Cashen, Anne Grand’Maison, Philip L. McCarthy, Paula M. Fracasso, Elliot Norry, Dennis Williams, Mihaela Druta, David A. Liebner, Kunle Odunsi, Marcus O. Butler - Nature Medicine 2023 被引用: 194

  13. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 149

  14. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 115

  15. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eunice L. Kwak, David S. Hong - Journal for ImmunoTherapy of Cancer 2022 被引用: 156

  16. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2020 被引用: 256

  17. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 391

  18. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 230

  19. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2015 被引用: 440

  20. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma

    著者: , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 212

  21. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 104

  22. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

    著者: , , , , , , , , , , , , , , - Nature Medicine 2023 被引用: 103

  23. Intratumoral Injection of Clostridium novyi -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mary Varterasian, Khashayarsha Khazaie, Mrinal M. Gounder - Clinical Cancer Research 2020 被引用: 155

  24. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2018 被引用: 288